Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria M Villaflor

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Cancer|June 15, 2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiationKevin S Choe, Daniel J Haraf, Abhishek Solanki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancerMichael D Hasselle, Daniel J Haraf, Kyle E Rusthoven, et al.
Future Oncology (London, England)|August 11, 2022
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumorsSantosh Kesari, Alberto Bessudo, Brian R Gastman, et al.
British Journal of Cancer|August 9, 2022
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinomaAri J Rosenberg, Nishant Agrawal, Alexander T Pearson, et al.
Oncotarget|May 29, 2018
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancerAri J Rosenberg, Derek A Wainwright, Alfred Rademaker, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Cancer|October 25, 2011
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic diseaseJoseph K Salama, Michael D Hasselle, Steven J Chmura, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck CancerTanguy Y Seiwert, James M Melotek, Elizabeth A Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Cancer|June 15, 2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiationKevin S Choe, Daniel J Haraf, Abhishek Solanki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancerMichael D Hasselle, Daniel J Haraf, Kyle E Rusthoven, et al.
Future Oncology (London, England)|August 11, 2022
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumorsSantosh Kesari, Alberto Bessudo, Brian R Gastman, et al.
British Journal of Cancer|August 9, 2022
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinomaAri J Rosenberg, Nishant Agrawal, Alexander T Pearson, et al.
Oncotarget|May 29, 2018
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancerAri J Rosenberg, Derek A Wainwright, Alfred Rademaker, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Cancer|October 25, 2011
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic diseaseJoseph K Salama, Michael D Hasselle, Steven J Chmura, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck CancerTanguy Y Seiwert, James M Melotek, Elizabeth A Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Pageof 5